Logo image of OCUP

OCUPHIRE PHARMA INC (OCUP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OCUP - US67577R1023 - Common Stock

1.17 USD
-0.16 (-12.03%)
Last: 10/23/2024, 8:00:03 PM
1.1601 USD
-0.01 (-0.85%)
After Hours: 10/23/2024, 8:00:03 PM
Fundamental Rating

3

Taking everything into account, OCUP scores 3 out of 10 in our fundamental rating. OCUP was compared to 190 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for OCUP as it has an excellent financial health rating, but there are worries on the profitability. OCUP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year OCUP has reported negative net income.
  • OCUP had a negative operating cash flow in the past year.
  • In the past 5 years OCUP reported 4 times negative net income.
  • In the past 5 years OCUP reported 4 times negative operating cash flow.
OCUP Yearly Net Income VS EBIT VS OCF VS FCFOCUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M

1.2 Ratios

  • With a Return On Assets value of -31.46%, OCUP perfoms like the industry average, outperforming 54.64% of the companies in the same industry.
  • The Return On Equity of OCUP (-34.71%) is better than 65.46% of its industry peers.
Industry RankSector Rank
ROA -31.46%
ROE -34.71%
ROIC N/A
ROA(3y)-66.45%
ROA(5y)-81.05%
ROE(3y)-78.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OCUP Yearly ROA, ROE, ROICOCUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

  • OCUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCUP Yearly Profit, Operating, Gross MarginsOCUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

8

2. Health

2.1 Basic Checks

  • OCUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OCUP has more shares outstanding than it did 1 year ago.
  • OCUP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
OCUP Yearly Shares OutstandingOCUP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
OCUP Yearly Total Debt VS Total AssetsOCUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

  • An Altman-Z score of 1.82 indicates that OCUP is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • The Altman-Z score of OCUP (1.82) is better than 64.43% of its industry peers.
  • OCUP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.82
ROIC/WACCN/A
WACC9.1%
OCUP Yearly LT Debt VS Equity VS FCFOCUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

  • A Current Ratio of 10.68 indicates that OCUP has no problem at all paying its short term obligations.
  • OCUP has a better Current ratio (10.68) than 80.93% of its industry peers.
  • OCUP has a Quick Ratio of 10.68. This indicates that OCUP is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of OCUP (10.68) is better than 80.93% of its industry peers.
Industry RankSector Rank
Current Ratio 10.68
Quick Ratio 10.68
OCUP Yearly Current Assets VS Current LiabilitesOCUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

3

3. Growth

3.1 Past

  • The earnings per share for OCUP have decreased strongly by -165.48% in the last year.
  • The Revenue for OCUP has decreased by -63.65% in the past year. This is quite bad
EPS 1Y (TTM)-165.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-63.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.73%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.62% on average over the next years. This is a very strong growth
  • OCUP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.52% yearly.
EPS Next Y-85.94%
EPS Next 2Y-38.1%
EPS Next 3Y10.72%
EPS Next 5Y41.62%
Revenue Next Year-44.06%
Revenue Next 2Y-18.88%
Revenue Next 3Y16.43%
Revenue Next 5Y42.52%

3.3 Evolution

OCUP Yearly Revenue VS EstimatesOCUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 50M 100M 150M 200M
OCUP Yearly EPS VS EstimatesOCUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • OCUP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCUP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCUP Price Earnings VS Forward Price EarningsOCUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCUP Per share dataOCUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-38.1%
EPS Next 3Y10.72%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for OCUP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUPHIRE PHARMA INC

NASDAQ:OCUP (10/23/2024, 8:00:03 PM)

After market: 1.1601 -0.01 (-0.85%)

1.17

-0.16 (-12.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-13
Earnings (Next)11-08
Inst Owners9.66%
Inst Owner Change0%
Ins Owners8.94%
Ins Owner Change0%
Market Cap30.65M
Revenue(TTM)16.45M
Net Income(TTM)-14.11M
Analysts82.22
Price Target17.09 (1360.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-63.76%
Min EPS beat(2)-112.17%
Max EPS beat(2)-15.34%
EPS beat(4)1
Avg EPS beat(4)-52.32%
Min EPS beat(4)-292.16%
Max EPS beat(4)210.41%
EPS beat(8)3
Avg EPS beat(8)-25.79%
EPS beat(12)6
Avg EPS beat(12)-13.86%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-58.11%
Min Revenue beat(2)-60.55%
Max Revenue beat(2)-55.68%
Revenue beat(4)1
Avg Revenue beat(4)25.38%
Min Revenue beat(4)-69.01%
Max Revenue beat(4)286.75%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.84%
EPS NQ rev (1m)0.98%
EPS NQ rev (3m)-11.4%
EPS NY rev (1m)0.85%
EPS NY rev (3m)-25.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-20.47%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)-22.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.86
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 0.75
EV/EBITDA N/A
EPS(TTM)-0.55
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.63
BVpS1.55
TBVpS1.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -31.46%
ROE -34.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.45%
ROA(5y)-81.05%
ROE(3y)-78.82%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.68
Quick Ratio 10.68
Altman-Z 1.82
F-Score3
WACC9.1%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-165.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-85.94%
EPS Next 2Y-38.1%
EPS Next 3Y10.72%
EPS Next 5Y41.62%
Revenue 1Y (TTM)-63.65%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-69.73%
Revenue Next Year-44.06%
Revenue Next 2Y-18.88%
Revenue Next 3Y16.43%
Revenue Next 5Y42.52%
EBIT growth 1Y-175.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-202.74%
EBIT Next 3Y73.4%
EBIT Next 5Y91.81%
FCF growth 1Y40.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.34%
OCF growth 3YN/A
OCF growth 5YN/A

OCUPHIRE PHARMA INC / OCUP FAQ

What is the ChartMill fundamental rating of OCUPHIRE PHARMA INC (OCUP) stock?

ChartMill assigns a fundamental rating of 4 / 10 to OCUP.


Can you provide the valuation status for OCUPHIRE PHARMA INC?

ChartMill assigns a valuation rating of 3 / 10 to OCUPHIRE PHARMA INC (OCUP). This can be considered as Overvalued.


Can you provide the profitability details for OCUPHIRE PHARMA INC?

OCUPHIRE PHARMA INC (OCUP) has a profitability rating of 1 / 10.